Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model
Septiara Putri, Ryan Rachmad Nugraha, Eka Pujiyanti, Hasbullah Thabrany, Hanifah Hasnur, Novita Dwi Istanti, Diah Evasari, Afiatin
Abstract
OBJECTIVE: Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are main modalities for end stage renal disease (ESRD) patients, and those have been covered by National Health Insurance (NHI) scheme since 2014 in Indonesia. This study aims to update the cost-effectiveness model of CAPD versus HD in Indonesia setting. RESULTS: Compared to HD, CAPD provides good value for money among ESRD patients in Indonesia. Using societal perspective, the total costs were IDR 1,348,612,118 (USD 95,504) and IDR 1,368,447,750 (USD 96,908), for CAPD and HD, respectively. The QALY was slightly different between two modalities, 4.79 for CAPD versus 4.22 for HD. The incremental cost-effectiveness ratio (ICER) yields savings of IDR 34,723,527/QALY (USD 2460).